 Timothy Benke
Concepts (493)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spasms, Infantile | 27 | 2024 | 105 | 6.390 |
Why?
| | Epileptic Syndromes | 22 | 2024 | 64 | 5.530 |
Why?
| | Seizures | 17 | 2023 | 344 | 3.320 |
Why?
| | Rett Syndrome | 16 | 2024 | 23 | 2.990 |
Why?
| | Epilepsy | 12 | 2023 | 290 | 2.870 |
Why?
| | Receptors, AMPA | 13 | 2023 | 120 | 2.260 |
Why?
| | Hippocampus | 20 | 2023 | 709 | 2.180 |
Why?
| | Long-Term Potentiation | 9 | 2022 | 145 | 1.720 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 11 | 2023 | 182 | 1.650 |
Why?
| | Vision Disorders | 8 | 2023 | 130 | 1.600 |
Why?
| | Synapses | 13 | 2023 | 336 | 1.370 |
Why?
| | Movement Disorders | 5 | 2023 | 46 | 1.360 |
Why?
| | Excitatory Postsynaptic Potentials | 11 | 2018 | 101 | 1.180 |
Why?
| | Cognition Disorders | 8 | 2019 | 475 | 1.060 |
Why?
| | Anticonvulsants | 6 | 2023 | 181 | 0.970 |
Why?
| | Neuropsychological Tests | 16 | 2020 | 919 | 0.950 |
Why?
| | Long-Term Synaptic Depression | 3 | 2014 | 48 | 0.930 |
Why?
| | CA1 Region, Hippocampal | 3 | 2022 | 29 | 0.930 |
Why?
| | Neurodevelopmental Disorders | 3 | 2021 | 109 | 0.910 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 4 | 2020 | 16 | 0.900 |
Why?
| | Receptors, Metabotropic Glutamate | 2 | 2014 | 35 | 0.890 |
Why?
| | Autistic Disorder | 3 | 2022 | 163 | 0.880 |
Why?
| | Social Behavior | 3 | 2015 | 269 | 0.860 |
Why?
| | Kainic Acid | 9 | 2020 | 31 | 0.850 |
Why?
| | Memory Disorders | 4 | 2014 | 155 | 0.760 |
Why?
| | Clinical Trials as Topic | 3 | 2022 | 941 | 0.730 |
Why?
| | Genetic Therapy | 1 | 2021 | 260 | 0.690 |
Why?
| | Developmental Disabilities | 2 | 2019 | 240 | 0.680 |
Why?
| | Rats, Sprague-Dawley | 12 | 2021 | 2262 | 0.650 |
Why?
| | Maze Learning | 3 | 2014 | 87 | 0.630 |
Why?
| | Neuronal Plasticity | 3 | 2018 | 214 | 0.620 |
Why?
| | Symptom Assessment | 1 | 2019 | 121 | 0.610 |
Why?
| | Mental Retardation, X-Linked | 3 | 2023 | 13 | 0.580 |
Why?
| | Schizophrenia | 1 | 2021 | 418 | 0.580 |
Why?
| | Cerebral Cortex | 7 | 2021 | 386 | 0.570 |
Why?
| | Rats | 19 | 2021 | 5034 | 0.570 |
Why?
| | Genomics | 1 | 2021 | 645 | 0.560 |
Why?
| | Animals | 38 | 2023 | 32102 | 0.530 |
Why?
| | Hair Cells, Vestibular | 4 | 2023 | 27 | 0.520 |
Why?
| | Methyl-CpG-Binding Protein 2 | 5 | 2023 | 11 | 0.510 |
Why?
| | Humans | 87 | 2024 | 115587 | 0.510 |
Why?
| | Severity of Illness Index | 6 | 2021 | 2578 | 0.480 |
Why?
| | Dementia | 4 | 2007 | 185 | 0.470 |
Why?
| | Psychometrics | 6 | 2024 | 615 | 0.460 |
Why?
| | Animals, Newborn | 9 | 2015 | 780 | 0.460 |
Why?
| | Child | 31 | 2024 | 18488 | 0.450 |
Why?
| | Electroencephalography | 12 | 2023 | 365 | 0.440 |
Why?
| | Disease Models, Animal | 8 | 2022 | 3580 | 0.440 |
Why?
| | Adrenocorticotropic Hormone | 3 | 2023 | 148 | 0.440 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 4 | 2016 | 158 | 0.440 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 1536 | 0.440 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2013 | 61 | 0.430 |
Why?
| | Male | 52 | 2023 | 55949 | 0.410 |
Why?
| | Behavior, Animal | 1 | 2015 | 472 | 0.390 |
Why?
| | Female | 51 | 2023 | 59913 | 0.390 |
Why?
| | Glutamic Acid | 4 | 2007 | 213 | 0.370 |
Why?
| | Child, Preschool | 18 | 2024 | 9133 | 0.360 |
Why?
| | Nervous System Diseases | 2 | 2023 | 253 | 0.360 |
Why?
| | Quality of Life | 6 | 2023 | 2385 | 0.360 |
Why?
| | Ion Channels | 4 | 2012 | 123 | 0.360 |
Why?
| | Chromosome Duplication | 2 | 2020 | 3 | 0.350 |
Why?
| | Calcium Channels, L-Type | 3 | 2022 | 107 | 0.340 |
Why?
| | Basal Ganglia Diseases | 2 | 2009 | 8 | 0.320 |
Why?
| | Excitatory Amino Acid Agonists | 4 | 2015 | 37 | 0.320 |
Why?
| | Surveys and Questionnaires | 7 | 2023 | 4665 | 0.320 |
Why?
| | Genetic Association Studies | 2 | 2020 | 343 | 0.310 |
Why?
| | Space Perception | 1 | 2008 | 62 | 0.300 |
Why?
| | Infant | 16 | 2024 | 7979 | 0.300 |
Why?
| | Brain Ischemia | 2 | 2009 | 298 | 0.300 |
Why?
| | Risk-Taking | 2 | 2009 | 332 | 0.300 |
Why?
| | Evoked Potentials, Visual | 3 | 2023 | 31 | 0.290 |
Why?
| | Mutation | 10 | 2023 | 3364 | 0.290 |
Why?
| | Neurons | 7 | 2023 | 1298 | 0.290 |
Why?
| | Dystonia | 1 | 2007 | 16 | 0.290 |
Why?
| | Memory, Short-Term | 2 | 2008 | 224 | 0.290 |
Why?
| | Models, Neurological | 6 | 2005 | 213 | 0.280 |
Why?
| | Membrane Potentials | 6 | 2023 | 251 | 0.280 |
Why?
| | Calcium | 6 | 2023 | 1103 | 0.280 |
Why?
| | Brain Abscess | 1 | 2006 | 11 | 0.270 |
Why?
| | Amnesia | 2 | 2005 | 42 | 0.270 |
Why?
| | Indans | 1 | 2005 | 9 | 0.260 |
Why?
| | Age Factors | 5 | 2020 | 2907 | 0.260 |
Why?
| | Cholinesterase Inhibitors | 1 | 2005 | 25 | 0.260 |
Why?
| | Prosencephalon | 1 | 2005 | 48 | 0.260 |
Why?
| | Phenotype | 8 | 2022 | 2829 | 0.260 |
Why?
| | Evoked Potentials | 3 | 2023 | 110 | 0.250 |
Why?
| | Aneurysm, Ruptured | 1 | 2005 | 34 | 0.250 |
Why?
| | Amobarbital | 1 | 2005 | 1 | 0.250 |
Why?
| | Amnesia, Transient Global | 1 | 2005 | 1 | 0.250 |
Why?
| | Adolescent | 22 | 2024 | 17889 | 0.250 |
Why?
| | Long QT Syndrome | 2 | 2022 | 59 | 0.250 |
Why?
| | Tissue Culture Techniques | 2 | 2015 | 67 | 0.250 |
Why?
| | Brain Diseases | 3 | 2023 | 127 | 0.240 |
Why?
| | Neurodegenerative Diseases | 1 | 2006 | 92 | 0.240 |
Why?
| | Patch-Clamp Techniques | 8 | 2015 | 245 | 0.240 |
Why?
| | Piperidines | 1 | 2005 | 163 | 0.230 |
Why?
| | Tetanus Toxin | 1 | 2004 | 5 | 0.230 |
Why?
| | Celiac Disease | 1 | 2007 | 266 | 0.230 |
Why?
| | Decision Making | 2 | 2009 | 791 | 0.230 |
Why?
| | Hypnotics and Sedatives | 1 | 2005 | 134 | 0.230 |
Why?
| | Signal Transduction | 2 | 2014 | 4541 | 0.230 |
Why?
| | Parvalbumins | 1 | 2023 | 19 | 0.220 |
Why?
| | Status Epilepticus | 1 | 2023 | 33 | 0.220 |
Why?
| | Adult | 27 | 2024 | 30718 | 0.220 |
Why?
| | Dendrites | 3 | 2007 | 85 | 0.220 |
Why?
| | Cerebral Aqueduct | 1 | 2003 | 3 | 0.220 |
Why?
| | Chromosomes, Human, X | 2 | 2023 | 60 | 0.220 |
Why?
| | Ventriculostomy | 1 | 2003 | 17 | 0.220 |
Why?
| | Learning | 1 | 2007 | 358 | 0.210 |
Why?
| | Vestibule, Labyrinth | 1 | 2023 | 54 | 0.210 |
Why?
| | Checklist | 1 | 2023 | 84 | 0.210 |
Why?
| | Pregnanolone | 1 | 2022 | 21 | 0.200 |
Why?
| | Disorders of Excessive Somnolence | 1 | 2022 | 25 | 0.200 |
Why?
| | Hydrocephalus | 1 | 2003 | 81 | 0.200 |
Why?
| | Anti-Anxiety Agents | 1 | 2022 | 44 | 0.200 |
Why?
| | Calcinosis | 1 | 2004 | 242 | 0.200 |
Why?
| | Phosphorylation | 3 | 2015 | 1571 | 0.200 |
Why?
| | Receptors, GABA-A | 1 | 2022 | 88 | 0.200 |
Why?
| | Alzheimer Disease | 1 | 2007 | 438 | 0.200 |
Why?
| | Acute Disease | 4 | 2015 | 914 | 0.200 |
Why?
| | Ultrasonics | 1 | 2021 | 48 | 0.200 |
Why?
| | Neurologists | 1 | 2021 | 18 | 0.190 |
Why?
| | Synaptic Transmission | 4 | 2023 | 232 | 0.190 |
Why?
| | Vision, Ocular | 1 | 2021 | 30 | 0.190 |
Why?
| | Sodium Channel Blockers | 1 | 2021 | 23 | 0.190 |
Why?
| | Visual Pathways | 1 | 2021 | 44 | 0.190 |
Why?
| | Corpus Callosum | 2 | 2019 | 57 | 0.190 |
Why?
| | Athletic Injuries | 1 | 2007 | 456 | 0.190 |
Why?
| | Memory | 3 | 2008 | 211 | 0.190 |
Why?
| | Brain | 9 | 2009 | 2370 | 0.190 |
Why?
| | Intellectual Disability | 1 | 2022 | 129 | 0.190 |
Why?
| | Pyramidal Cells | 3 | 2015 | 51 | 0.190 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2020 | 22 | 0.180 |
Why?
| | Subcellular Fractions | 2 | 2013 | 78 | 0.180 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2019 | 27 | 0.180 |
Why?
| | In Vitro Techniques | 6 | 2013 | 1044 | 0.180 |
Why?
| | Endoscopy | 1 | 2003 | 247 | 0.180 |
Why?
| | Autism Spectrum Disorder | 2 | 2022 | 322 | 0.180 |
Why?
| | Epilepsy, Temporal Lobe | 3 | 2005 | 21 | 0.180 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2022 | 116 | 0.180 |
Why?
| | Follow-Up Studies | 8 | 2021 | 4440 | 0.180 |
Why?
| | Electrophysiology | 5 | 2007 | 202 | 0.170 |
Why?
| | Magnetic Resonance Imaging | 10 | 2010 | 3069 | 0.170 |
Why?
| | Cyclins | 1 | 2020 | 79 | 0.170 |
Why?
| | Analysis of Variance | 5 | 2009 | 1227 | 0.170 |
Why?
| | Pediatrics | 1 | 2007 | 986 | 0.170 |
Why?
| | Action Potentials | 6 | 2023 | 410 | 0.170 |
Why?
| | Parkinson Disease | 5 | 2011 | 325 | 0.170 |
Why?
| | Blotting, Western | 2 | 2015 | 1153 | 0.170 |
Why?
| | Speech Disorders | 1 | 2019 | 31 | 0.160 |
Why?
| | Double-Blind Method | 5 | 2023 | 1660 | 0.160 |
Why?
| | Vagus Nerve Stimulation | 1 | 2019 | 22 | 0.160 |
Why?
| | Diet, Ketogenic | 1 | 2019 | 33 | 0.160 |
Why?
| | Gene Duplication | 1 | 2019 | 62 | 0.160 |
Why?
| | Stroke | 1 | 2007 | 1016 | 0.160 |
Why?
| | Sleep Wake Disorders | 1 | 2022 | 233 | 0.160 |
Why?
| | Glutamates | 3 | 2023 | 59 | 0.160 |
Why?
| | Motor Activity | 2 | 2020 | 633 | 0.160 |
Why?
| | Syndrome | 3 | 2020 | 339 | 0.160 |
Why?
| | Face | 1 | 2020 | 167 | 0.160 |
Why?
| | Child Behavior | 1 | 2020 | 218 | 0.160 |
Why?
| | Reproducibility of Results | 5 | 2024 | 2800 | 0.160 |
Why?
| | Delphi Technique | 1 | 2019 | 164 | 0.160 |
Why?
| | Judgment | 1 | 2018 | 55 | 0.150 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 69 | 0.150 |
Why?
| | Communication | 1 | 2023 | 750 | 0.150 |
Why?
| | Treatment Outcome | 7 | 2023 | 9159 | 0.150 |
Why?
| | Aphasia | 3 | 2004 | 19 | 0.150 |
Why?
| | Alternative Splicing | 1 | 2019 | 187 | 0.150 |
Why?
| | Syncope, Vasovagal | 1 | 1997 | 3 | 0.140 |
Why?
| | Delusions | 1 | 1997 | 9 | 0.140 |
Why?
| | Gastrointestinal Diseases | 1 | 2019 | 184 | 0.140 |
Why?
| | Epilepsy, Generalized | 1 | 1997 | 13 | 0.140 |
Why?
| | Memantine | 2 | 2012 | 16 | 0.140 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 495 | 0.140 |
Why?
| | Epilepsies, Partial | 1 | 1997 | 31 | 0.140 |
Why?
| | Genetic Variation | 1 | 2021 | 877 | 0.140 |
Why?
| | Mice | 7 | 2023 | 15052 | 0.140 |
Why?
| | Protein Conformation | 1 | 2019 | 822 | 0.130 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 273 | 0.130 |
Why?
| | Time Factors | 9 | 2009 | 6165 | 0.130 |
Why?
| | Young Adult | 8 | 2024 | 10470 | 0.130 |
Why?
| | Time | 1 | 2015 | 72 | 0.130 |
Why?
| | Sex Factors | 2 | 2019 | 1736 | 0.130 |
Why?
| | Brain Damage, Chronic | 1 | 1995 | 19 | 0.130 |
Why?
| | Precision Medicine | 1 | 2019 | 344 | 0.130 |
Why?
| | Lyme Disease | 1 | 1995 | 32 | 0.120 |
Why?
| | Organ Culture Techniques | 2 | 2016 | 143 | 0.120 |
Why?
| | Meningitis, Bacterial | 1 | 1995 | 49 | 0.120 |
Why?
| | N-Methylaspartate | 2 | 1996 | 37 | 0.120 |
Why?
| | Anxiety | 3 | 2022 | 853 | 0.120 |
Why?
| | Membrane Proteins | 3 | 2010 | 1024 | 0.120 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2014 | 21 | 0.120 |
Why?
| | Calmodulin | 1 | 2014 | 72 | 0.120 |
Why?
| | Mental Recall | 3 | 2007 | 173 | 0.110 |
Why?
| | Models, Molecular | 1 | 2019 | 1390 | 0.110 |
Why?
| | Pregnancy | 3 | 2013 | 5548 | 0.110 |
Why?
| | Mutation, Missense | 3 | 2023 | 296 | 0.110 |
Why?
| | Conotoxins | 1 | 1993 | 4 | 0.110 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2014 | 136 | 0.110 |
Why?
| | Spasm | 2 | 2023 | 19 | 0.110 |
Why?
| | Demyelinating Diseases | 1 | 1994 | 75 | 0.110 |
Why?
| | Retrospective Studies | 7 | 2023 | 12608 | 0.110 |
Why?
| | Protein Phosphatase 2 | 1 | 2013 | 30 | 0.110 |
Why?
| | Middle Aged | 14 | 2018 | 26999 | 0.110 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2013 | 36 | 0.110 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 157 | 0.110 |
Why?
| | Down Syndrome | 2 | 2022 | 336 | 0.110 |
Why?
| | Angiostrongylus cantonensis | 1 | 2013 | 3 | 0.110 |
Why?
| | Strongylida Infections | 1 | 2013 | 6 | 0.110 |
Why?
| | Thiazoles | 1 | 2013 | 110 | 0.110 |
Why?
| | Caregivers | 3 | 2023 | 713 | 0.110 |
Why?
| | Functional Laterality | 4 | 2009 | 201 | 0.110 |
Why?
| | MAP Kinase Signaling System | 1 | 2014 | 275 | 0.100 |
Why?
| | Meningitis | 1 | 2013 | 74 | 0.100 |
Why?
| | Presynaptic Terminals | 2 | 2009 | 55 | 0.100 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 362 | 0.100 |
Why?
| | Dopaminergic Neurons | 1 | 2011 | 43 | 0.100 |
Why?
| | Genotype | 3 | 2022 | 1786 | 0.100 |
Why?
| | Disks Large Homolog 4 Protein | 2 | 2009 | 16 | 0.090 |
Why?
| | Cellular Reprogramming | 1 | 2011 | 84 | 0.090 |
Why?
| | Infant, Newborn | 3 | 2022 | 5077 | 0.090 |
Why?
| | Eosinophilia | 1 | 2013 | 186 | 0.090 |
Why?
| | Leukoencephalopathies | 1 | 2010 | 21 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2013 | 757 | 0.090 |
Why?
| | Pyridines | 1 | 2013 | 425 | 0.090 |
Why?
| | Dominance, Cerebral | 1 | 1989 | 50 | 0.090 |
Why?
| | Prognosis | 3 | 2022 | 3339 | 0.090 |
Why?
| | Guanylate Kinases | 1 | 2009 | 13 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 93 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 66 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2006 | 1357 | 0.080 |
Why?
| | Mathematical Concepts | 1 | 2009 | 22 | 0.080 |
Why?
| | Aged | 10 | 2022 | 19251 | 0.080 |
Why?
| | Reaction Time | 2 | 2009 | 373 | 0.080 |
Why?
| | Language Disorders | 2 | 2007 | 32 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2006 | 3022 | 0.080 |
Why?
| | Receptors, Cholinergic | 1 | 2008 | 41 | 0.080 |
Why?
| | A Kinase Anchor Proteins | 1 | 2009 | 65 | 0.080 |
Why?
| | Uncertainty | 1 | 2009 | 97 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 2 | 2009 | 388 | 0.080 |
Why?
| | Cells, Cultured | 7 | 2017 | 3914 | 0.080 |
Why?
| | Gerbillinae | 3 | 2017 | 61 | 0.080 |
Why?
| | Exploratory Behavior | 1 | 2008 | 86 | 0.080 |
Why?
| | Conditioning, Classical | 1 | 2008 | 87 | 0.080 |
Why?
| | Vertebral Artery Dissection | 1 | 2007 | 18 | 0.070 |
Why?
| | Mossy Fibers, Hippocampal | 1 | 2007 | 5 | 0.070 |
Why?
| | Neuromuscular Diseases | 1 | 2008 | 90 | 0.070 |
Why?
| | Jejunum | 1 | 2007 | 24 | 0.070 |
Why?
| | Shy-Drager Syndrome | 1 | 2007 | 1 | 0.070 |
Why?
| | Games, Experimental | 1 | 2007 | 9 | 0.070 |
Why?
| | Periodicity | 1 | 2007 | 56 | 0.070 |
Why?
| | Soccer | 1 | 2007 | 34 | 0.070 |
Why?
| | Fibroblasts | 1 | 2011 | 839 | 0.070 |
Why?
| | Glutens | 1 | 2007 | 56 | 0.070 |
Why?
| | Strontium | 3 | 2017 | 14 | 0.070 |
Why?
| | Prospective Studies | 4 | 2022 | 6264 | 0.070 |
Why?
| | Antibodies | 1 | 2008 | 374 | 0.070 |
Why?
| | Football | 1 | 2007 | 77 | 0.070 |
Why?
| | Cross-Linking Reagents | 1 | 2007 | 182 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2007 | 489 | 0.070 |
Why?
| | Bumetanide | 1 | 2005 | 2 | 0.070 |
Why?
| | Secondary Prevention | 1 | 2007 | 223 | 0.070 |
Why?
| | Length of Stay | 1 | 2010 | 958 | 0.070 |
Why?
| | Sodium Potassium Chloride Symporter Inhibitors | 1 | 2005 | 12 | 0.070 |
Why?
| | Pilot Projects | 2 | 2012 | 1377 | 0.070 |
Why?
| | Biomarkers | 2 | 2021 | 3466 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2007 | 1642 | 0.060 |
Why?
| | Fear | 1 | 2008 | 297 | 0.060 |
Why?
| | Organ of Corti | 1 | 2005 | 14 | 0.060 |
Why?
| | Language | 1 | 2008 | 258 | 0.060 |
Why?
| | Receptors, Kainic Acid | 1 | 2005 | 10 | 0.060 |
Why?
| | Diuretics | 1 | 2005 | 67 | 0.060 |
Why?
| | Hair Cells, Auditory | 1 | 2005 | 39 | 0.060 |
Why?
| | Auditory Pathways | 1 | 2005 | 54 | 0.060 |
Why?
| | Parents | 2 | 2023 | 1205 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2007 | 485 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 390 | 0.060 |
Why?
| | Ion Channel Gating | 1 | 2005 | 83 | 0.060 |
Why?
| | Thalamus | 1 | 2005 | 78 | 0.060 |
Why?
| | Tomography, Emission-Computed | 1 | 2004 | 58 | 0.060 |
Why?
| | Encephalitis, Viral | 1 | 2004 | 39 | 0.060 |
Why?
| | Simplexvirus | 1 | 2004 | 82 | 0.060 |
Why?
| | Nerve Net | 1 | 2007 | 228 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2023 | 2604 | 0.060 |
Why?
| | Sodium | 1 | 2005 | 183 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2004 | 88 | 0.060 |
Why?
| | Protein Binding | 3 | 2016 | 1917 | 0.060 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2004 | 125 | 0.060 |
Why?
| | Muscle Hypotonia | 1 | 2023 | 31 | 0.060 |
Why?
| | Failure to Thrive | 1 | 2023 | 32 | 0.060 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2023 | 60 | 0.060 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 724 | 0.060 |
Why?
| | Biopsy | 1 | 2007 | 1056 | 0.060 |
Why?
| | Stereotypic Movement Disorder | 1 | 2003 | 6 | 0.050 |
Why?
| | Thirst | 1 | 2003 | 5 | 0.050 |
Why?
| | Radiopharmaceuticals | 1 | 2004 | 187 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2010 | 1700 | 0.050 |
Why?
| | Vigabatrin | 1 | 2023 | 18 | 0.050 |
Why?
| | Drinking | 1 | 2003 | 33 | 0.050 |
Why?
| | Motor Skills | 1 | 2024 | 80 | 0.050 |
Why?
| | Electric Conductivity | 2 | 2004 | 91 | 0.050 |
Why?
| | Third Ventricle | 1 | 2003 | 14 | 0.050 |
Why?
| | Neurons, Afferent | 1 | 2023 | 88 | 0.050 |
Why?
| | Syndactyly | 1 | 2022 | 10 | 0.050 |
Why?
| | Neurologic Examination | 1 | 2003 | 116 | 0.050 |
Why?
| | Interneurons | 1 | 2023 | 99 | 0.050 |
Why?
| | Aggression | 1 | 2004 | 185 | 0.050 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2023 | 110 | 0.050 |
Why?
| | Miniature Postsynaptic Potentials | 2 | 2014 | 9 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 528 | 0.050 |
Why?
| | X Chromosome Inactivation | 1 | 2022 | 21 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2003 | 210 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2022 | 134 | 0.050 |
Why?
| | Vocalization, Animal | 1 | 2021 | 28 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2023 | 147 | 0.050 |
Why?
| | Comorbidity | 2 | 2022 | 1473 | 0.050 |
Why?
| | Patient Acuity | 1 | 2021 | 42 | 0.050 |
Why?
| | Mammals | 1 | 2023 | 251 | 0.050 |
Why?
| | Anthropometry | 1 | 2022 | 181 | 0.050 |
Why?
| | Cohort Studies | 2 | 2021 | 4944 | 0.050 |
Why?
| | Artifacts | 1 | 2001 | 122 | 0.050 |
Why?
| | Cerebral Palsy | 1 | 2022 | 78 | 0.050 |
Why?
| | RNA Interference | 2 | 2014 | 438 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2022 | 324 | 0.040 |
Why?
| | Forecasting | 1 | 2001 | 333 | 0.040 |
Why?
| | Genetic Testing | 1 | 2022 | 382 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 1 | 2021 | 173 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 509 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 560 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 443 | 0.040 |
Why?
| | Head Injuries, Closed | 1 | 1999 | 48 | 0.040 |
Why?
| | Inflammation | 1 | 2009 | 2499 | 0.040 |
Why?
| | Interviews as Topic | 1 | 2021 | 596 | 0.040 |
Why?
| | Vesicular Transport Proteins | 1 | 1999 | 83 | 0.040 |
Why?
| | Cost of Illness | 1 | 2020 | 257 | 0.040 |
Why?
| | Risk Factors | 3 | 2009 | 8697 | 0.040 |
Why?
| | Risk Assessment | 1 | 2007 | 2987 | 0.040 |
Why?
| | Family | 1 | 2022 | 594 | 0.040 |
Why?
| | Walking | 1 | 2022 | 425 | 0.040 |
Why?
| | Chronic Disease | 1 | 2004 | 1598 | 0.040 |
Why?
| | Emotions | 1 | 2022 | 477 | 0.040 |
Why?
| | Benzothiadiazines | 1 | 2017 | 3 | 0.040 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 11 | 0.040 |
Why?
| | Nifedipine | 1 | 2017 | 29 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2005 | 980 | 0.040 |
Why?
| | Dipeptides | 1 | 2017 | 49 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2018 | 434 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2007 | 6417 | 0.030 |
Why?
| | Quinoxalines | 1 | 2017 | 61 | 0.030 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 115 | 0.030 |
Why?
| | Nerve Tissue Proteins | 2 | 2011 | 535 | 0.030 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 1996 | 89 | 0.030 |
Why?
| | Models, Biological | 1 | 2023 | 1646 | 0.030 |
Why?
| | Language Tests | 2 | 2007 | 31 | 0.030 |
Why?
| | Awareness | 1 | 1997 | 92 | 0.030 |
Why?
| | Psychomotor Performance | 1 | 2018 | 278 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 2 | 2009 | 100 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2001 | 380 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2016 | 271 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1999 | 701 | 0.030 |
Why?
| | Neurocognitive Disorders | 1 | 1995 | 23 | 0.030 |
Why?
| | Dendritic Cells | 1 | 1998 | 438 | 0.030 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2005 | 130 | 0.030 |
Why?
| | Adenoviridae | 1 | 1996 | 186 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 1996 | 148 | 0.030 |
Why?
| | Peptides | 2 | 2016 | 864 | 0.030 |
Why?
| | Genetic Vectors | 1 | 1996 | 290 | 0.030 |
Why?
| | Electric Stimulation | 2 | 2005 | 263 | 0.030 |
Why?
| | Mollusk Venoms | 1 | 1993 | 1 | 0.030 |
Why?
| | Ibotenic Acid | 1 | 1993 | 6 | 0.030 |
Why?
| | 2-Amino-5-phosphonovalerate | 1 | 1993 | 10 | 0.030 |
Why?
| | Atrophy | 1 | 1994 | 152 | 0.030 |
Why?
| | Neural Pathways | 2 | 2005 | 260 | 0.030 |
Why?
| | Pyramidal Tracts | 1 | 1993 | 20 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2014 | 257 | 0.030 |
Why?
| | Heart Diseases | 1 | 1997 | 330 | 0.030 |
Why?
| | Point Mutation | 1 | 2014 | 217 | 0.030 |
Why?
| | DNA, Helminth | 1 | 2013 | 16 | 0.030 |
Why?
| | Magnesium | 1 | 1993 | 145 | 0.030 |
Why?
| | Reading | 1 | 1994 | 149 | 0.030 |
Why?
| | Cerebral Infarction | 2 | 1989 | 39 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2009 | 794 | 0.030 |
Why?
| | Green Fluorescent Proteins | 1 | 2014 | 377 | 0.030 |
Why?
| | Aging | 2 | 2021 | 1631 | 0.030 |
Why?
| | Cyclic GMP | 1 | 2012 | 80 | 0.030 |
Why?
| | Cerebellum | 1 | 1994 | 200 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2014 | 793 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2003 | 2161 | 0.030 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2011 | 8 | 0.030 |
Why?
| | Memory, Episodic | 1 | 2012 | 38 | 0.030 |
Why?
| | Transfection | 2 | 2009 | 866 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2014 | 544 | 0.020 |
Why?
| | Protein Processing, Post-Translational | 1 | 2014 | 401 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2012 | 227 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1993 | 262 | 0.020 |
Why?
| | Levodopa | 1 | 1991 | 23 | 0.020 |
Why?
| | SOXB1 Transcription Factors | 1 | 2011 | 60 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 1970 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 4435 | 0.020 |
Why?
| | Trihexyphenidyl | 1 | 1991 | 1 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1000 | 0.020 |
Why?
| | Aphasia, Wernicke | 1 | 1989 | 2 | 0.020 |
Why?
| | Anomia | 1 | 1989 | 2 | 0.020 |
Why?
| | Aphasia, Broca | 1 | 1989 | 3 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 54 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2011 | 225 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 3 | 2004 | 2392 | 0.020 |
Why?
| | Pyrimidines | 1 | 2012 | 376 | 0.020 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2009 | 81 | 0.020 |
Why?
| | Dopamine | 1 | 2011 | 237 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 372 | 0.020 |
Why?
| | Dendritic Spines | 1 | 2009 | 49 | 0.020 |
Why?
| | Germ Cells | 1 | 2009 | 61 | 0.020 |
Why?
| | Calcineurin | 1 | 2009 | 84 | 0.020 |
Why?
| | Austria | 1 | 2008 | 2 | 0.020 |
Why?
| | Switzerland | 1 | 2008 | 18 | 0.020 |
Why?
| | Luminescent Proteins | 1 | 2009 | 169 | 0.020 |
Why?
| | Age of Onset | 1 | 2009 | 450 | 0.020 |
Why?
| | Netherlands | 1 | 2008 | 64 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2008 | 147 | 0.020 |
Why?
| | Probability | 1 | 2009 | 294 | 0.020 |
Why?
| | Homeodomain Proteins | 1 | 2011 | 465 | 0.020 |
Why?
| | Germany | 1 | 2008 | 86 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2009 | 299 | 0.020 |
Why?
| | Alcoholism | 1 | 1994 | 713 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2009 | 364 | 0.020 |
Why?
| | United States | 1 | 2023 | 12295 | 0.020 |
Why?
| | Cerebral Hemorrhage | 1 | 1988 | 96 | 0.020 |
Why?
| | Cerebrovascular Disorders | 1 | 1988 | 82 | 0.020 |
Why?
| | Picrotoxin | 1 | 2007 | 13 | 0.020 |
Why?
| | GABA Antagonists | 1 | 2007 | 32 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2008 | 249 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2016 | 4773 | 0.020 |
Why?
| | Electromyography | 1 | 2008 | 324 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2009 | 804 | 0.020 |
Why?
| | Solute Carrier Family 12, Member 2 | 1 | 2005 | 7 | 0.020 |
Why?
| | Brain Mapping | 1 | 1989 | 521 | 0.020 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2005 | 9 | 0.020 |
Why?
| | Phenobarbital | 1 | 2005 | 17 | 0.020 |
Why?
| | Electric Capacitance | 1 | 2005 | 7 | 0.020 |
Why?
| | Turtles | 1 | 2005 | 11 | 0.020 |
Why?
| | Sclerosis | 1 | 2005 | 11 | 0.020 |
Why?
| | Epilepsy, Tonic-Clonic | 1 | 2005 | 4 | 0.020 |
Why?
| | Head Movements | 1 | 2005 | 18 | 0.020 |
Why?
| | Rats, Long-Evans | 1 | 2005 | 100 | 0.020 |
Why?
| | Videotape Recording | 1 | 2005 | 30 | 0.020 |
Why?
| | Egtazic Acid | 1 | 2005 | 44 | 0.020 |
Why?
| | Synaptic Vesicles | 1 | 2005 | 37 | 0.020 |
Why?
| | Cadmium | 1 | 2005 | 58 | 0.020 |
Why?
| | Basal Ganglia | 1 | 2005 | 42 | 0.020 |
Why?
| | Chelating Agents | 1 | 2005 | 71 | 0.020 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2005 | 138 | 0.020 |
Why?
| | Aspartic Acid | 1 | 2005 | 79 | 0.020 |
Why?
| | Neural Conduction | 1 | 2005 | 79 | 0.020 |
Why?
| | Rotation | 1 | 2005 | 113 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2005 | 140 | 0.020 |
Why?
| | Video Recording | 1 | 2005 | 147 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2011 | 2194 | 0.010 |
Why?
| | Posture | 1 | 2005 | 150 | 0.010 |
Why?
| | Reference Values | 2 | 1999 | 744 | 0.010 |
Why?
| | Acyclovir | 1 | 2004 | 100 | 0.010 |
Why?
| | Vomiting | 1 | 2004 | 125 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1528 | 0.010 |
Why?
| | Drug Interactions | 1 | 2005 | 347 | 0.010 |
Why?
| | Attention | 1 | 2007 | 394 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2335 | 0.010 |
Why?
| | Fever | 1 | 2004 | 280 | 0.010 |
Why?
| | Monitoring, Intraoperative | 1 | 2003 | 39 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 1870 | 0.010 |
Why?
| | Diagnostic Imaging | 1 | 2005 | 296 | 0.010 |
Why?
| | Prevalence | 1 | 2007 | 2264 | 0.010 |
Why?
| | Computer Simulation | 1 | 2005 | 881 | 0.010 |
Why?
| | Blood Pressure | 1 | 2007 | 1537 | 0.010 |
Why?
| | Colorado | 1 | 2009 | 4113 | 0.010 |
Why?
| | N-Ethylmaleimide-Sensitive Proteins | 1 | 1999 | 5 | 0.010 |
Why?
| | Water | 1 | 2003 | 412 | 0.010 |
Why?
| | Disease Progression | 1 | 2005 | 2418 | 0.010 |
Why?
| | Rats, Wistar | 1 | 1998 | 368 | 0.010 |
Why?
| | Dizocilpine Maleate | 1 | 1996 | 15 | 0.010 |
Why?
| | Binding, Competitive | 1 | 1996 | 200 | 0.010 |
Why?
| | beta-Galactosidase | 1 | 1996 | 63 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1996 | 1243 | 0.010 |
Why?
| | Kinetics | 1 | 1996 | 1569 | 0.010 |
Why?
| | Cell Survival | 1 | 1996 | 1024 | 0.010 |
Why?
| | Brain Concussion | 1 | 1999 | 469 | 0.010 |
Why?
| | Receptors, Dopamine | 1 | 1991 | 12 | 0.010 |
Why?
| | Intelligence Tests | 1 | 1991 | 59 | 0.010 |
Why?
| | Psychological Tests | 1 | 1991 | 123 | 0.010 |
Why?
| | Frontal Lobe | 1 | 1991 | 139 | 0.010 |
Why?
| | Kidney | 1 | 1996 | 1207 | 0.010 |
Why?
| | Cerebral Ventricles | 1 | 1988 | 47 | 0.000 |
Why?
| | Hypertension | 1 | 1988 | 1064 | 0.000 |
Why?
|
|
Benke's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|